- Home
- HNVR vs ARCT Comparison
HNVR vs ARCT Comparison
Compare HNVR & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNVR | ARCT |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.6M | 206.0M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HNVR | ARCT |
|---|---|---|
| Price | $20.20 | $6.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $24.50 | ★ $28.33 |
| AVG Volume (30 Days) | 5.5K | ★ 413.9K |
| Earning Date | 04-30-2026 | 06-08-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | $28.03 | $0.34 |
| Revenue Next Year | $8.02 | $93.19 |
| P/E Ratio | $20.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.31 | $5.85 |
| 52 Week High | $24.36 | $24.14 |
Technical Indicators
Market Signals| Indicator | HNVR | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 36.96 |
| Support Level | $20.48 | $5.93 |
| Resistance Level | $21.01 | $7.88 |
| Average True Range (ATR) | 0.52 | 0.47 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 28.63 | 1.99 |
Price Performance
Historical ComparisonAbout HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.